Industries > Pharma > Global Translational Regenerative Medicine Market Prospects 2018-2028

Global Translational Regenerative Medicine Market Prospects 2018-2028

Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

PUBLISHED: 27 March 2018
PAGES: 306
PRODUCT CODE: PHA0296

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 22.1% in the first half of the forecast period. Stem cell therapies accounted for the majority of the revenue in the market with an estimated market share of 56.0% in 2017.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 306-page report you will receive 109 tables and 67 figures – all unavailable elsewhere.

The 306-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Translational Regenerative Medicine market forecasts from 2018-2028

• Global Translational Regenerative Medicine submarket forecasts from 2018-2028 covering:
• Stem Cell Therapies
• Tissue Engineered Products
• Gene Therapies

This study discusses the late-state clinical trials and pipeline as well as market drivers and restraints of each submarket.

• Translational Regenerative Medicine regional market forecasts from 2018-2028, covering:
• United States
• Europe
• Asia-Pacific
• Rest of the World

• Forecasts from 2018-2028 of the leading products in the Global Translational Regenerative Medicine market:
• Osteocel Plus
• Trinity ELITE
• TEMCELL /Prochymal
• Apligraf
• Dermagraft
• Epifix
• ReCell
• Neovasculgen
• Glybera (alipogene tiparvovec)
• IMLYGIC (talimogene laherparepvec)

Global Translational Regenerative Medicine Market Prospects 2018-2028

• Assessment of the leading companies in the Global Translational Regenerative Medicine market:
• Alphatec Spine
• Anterogen
• Athersys
• Avita Medical
• AxoGen
• Medipost
• Mesoblast
• NuVasive
• Ocata Therapeutics
• Organogenesis
• Pharmicell
• Regenerys
• TiGenix
• UniQure
• Vericel Corporation

• Information on current developments, current advancements and current key approvals in the field of translational regenerative medicine market.

SWOT and Porter’s Five Force analysis of the translational regenerative medicine market

Visiongain’s study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.

Buy our report today Global Translational Regenerative Medicine Market Prospects 2018-2028: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Translational Regenerative Medicine Market Prospects 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Translational Regenerative Medicine Market Prospects 2018-2028


Latest Pharma news

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

READ

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

READ

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

READ

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

READ

Categories

Category